Evidence map›Paper›PMID 34401741›Full record

ArticleVaccine: X2021

Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives.

Kara M Plotnikoff, Robine Donken, Laurie Smith, Caroline Cameron, D Scott LaMontagne, Julie A Bettinger, Manish Sadarangani, Troy Grennan, C Sarai Racey, Kevin Hybiske and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Kara M PlotnikoffSchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Robine DonkenSchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Laurie SmithWomen's Health Research Institute, British Columbia Women's Hospital and Health Centre, Vancouver, BC, Canada.
Caroline CameronDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
D Scott LaMontagnePATH, Center for Vaccine Innovation & Access, Seattle, WA, USA.
Julie A BettingerWomen's Health Research Institute, British Columbia Women's Hospital and Health Centre, Vancouver, BC, Canada.
Manish SadaranganiVaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Troy GrennanDivision of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada.
C Sarai RaceySchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Kevin HybiskeDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
Monika NausSchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Amanda MonteiroWomen's Health Research Institute, British Columbia Women's Hospital and Health Centre, Vancouver, BC, Canada.
Gina S OgilvieSchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
University of British Columbia · CABC Children's Hospital · CAUniversity of Washington · USWomen's Health Research Institute · CABC Centre for Disease Control · CAProgram for Appropriate Technology in Health · US

Funding

Extracellular Matrix Adhesins of Treponema pallidumR37AI051334 · NIAID · UNIVERSITY OF VICTORIA · PI CAROLINE E CAMERON · 2019 to 2026
$2.3M
NIAID NIH HHS R37 AI051334
6 · The paper itself

Abstract

objectiveTo determine the sexually transmitted infection (STI) vaccine research priorities of global leaders in STI vaccine research, development, and service provision.

methodsGlobal representatives attending the

resultsA total of 46 out of 97 (44%) symposium attendees responded to the survey. Gonorrhea was identified as the STI that should be prioritized for vaccine development, followed by syphilis with weighted value scores of 3.82 and 3.37, respectively, out of a maximum of five. Basic science (and vaccine development) was the domain ranked with the highest priority with a weighted value score of 4.78 out of six. Research activities related to basic science and vaccine development (including pre-clinical and clinical trials, and surveillance measures) and increased funding opportunities were the most highly ranked activities in the "STI vaccine development" and "research domains and activities" categories.

conclusionGlobal leaders in attendance at the

Indexed as

PreventionPrioritiesPublic healthSexually transmitted infectionsVaccines

Identifiers

PMID34401741
PMCPMC8356130
OpenAlexW3173485796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.